Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 11/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 9/20 | 0.53 |
| ▸ | EGFR | P00533 | 8/20 | 0.47 |
| ▸ | FLT1 | P17948 | 8/20 | 0.47 |
| ▸ | LYN | P07948 | 5/20 | 0.44 |
| ▸ | PRKCB | P05771 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PRKCH | P24723 | 1/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518096 | 0.85 | PRKCQ (0.71) | PRKCQPRKCDEGFRFLT1LYN | |
| SCHEMBL5530012 | 0.85 | PRKCQ (0.69) | PRKCQPRKCDEGFRFLT1LYN | |
| SCHEMBL5530088 | 0.84 | PRKCQ (0.57) | PRKCQPRKCDEGFRFLT1LYN | |
| SCHEMBL5517828 | 0.83 | PRKCQ (0.70) | PRKCQPRKCDEGFRFLT1LYN | |
| SCHEMBL5515804 | 0.83 | PRKCQ (0.51) | PRKCQPRKCDEGFRFLT1LYN | |
| SCHEMBL5523867 | 0.81 | PRKCQ (0.55) | PRKCQPRKCDEGFRFLT1LYN | |
| SCHEMBL5522692 | 0.81 | PRKCQ (0.53) | PRKCQPRKCDEGFRFLT1LYN | |
| SCHEMBL5524928 | 0.81 | PRKCQ (0.55) | PRKCQPRKCDEGFRFLT1LYN | |
| SCHEMBL5518140 | 0.81 | PRKCQ (0.51) | PRKCQPRKCDEGFRFLT1LYN | |
| SCHEMBL5517780 | 0.80 | EGFR (0.62) | PRKCQPRKCDEGFRFLT1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | MAP4K2, CNKSR1, MAP3K1 | PRKCQ 286/4885PRKCD 356/4885EGFR 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.